In:
Journal of 108 - Clinical Medicine and Phamarcy, 108 Institute of Clinical Medical and Pharmaceutical Sciences, ( 2023-02-27)
Abstract:
Objective: To investigate the change in serum ubiquitin C-terminal hydrolase-L1 protein (UCH-L1) levels in severe traumatic brain injury patients. Subject and method: Thirty-nine patients with severe traumatic brain injury were treated at the surgical critical care department, 103 Military Hospital. The patients were treated to the protocol, and information was collected in the medical records for research and testing. UCH-L1 at time T0, T1, T2, T3, T4 and T5. A prospective cohort study. Result: Serum UCH-L1 concentration gradually increased from T0 (9.18ng/mL) to T1 (11.59ng/mL) and peaked at T2 (19.9ng/mL), then gradually decreased over time. The median serum UCH-L1 concentration in the surviving group was constantly lower than in the death group. The biggest difference observed at T1 (10.47ng/mL and 46.76ng/mL), however, was not statistically significant with p=0.063, while the difference was statistically significant at T3, T4, and T5. Conclusion: Serum UCH-L1 levels in patients with severe TBI increased gradually from T0 to T1 and peaked at T2, then gradually decreased at T5. Serum UCH-L1 levels in the surviving group were constantly lower than those in the death group, but there was no significant difference between T0, T1, and T2, whereas at points between T3, T4, and T5, the difference was statistically significant.
Type of Medium:
Online Resource
ISSN:
1859-2872
DOI:
10.52389/ydls.v17iTA
DOI:
10.52389/ydls.v17iTA.1657
Language:
Unknown
Publisher:
108 Institute of Clinical Medical and Pharmaceutical Sciences
Publication Date:
2023
Permalink
